Valuation : Theracryf Plc

Market Cap 5.52M 4.76M 4.48M 4.08M 7.68M 524M 7.72M 52.98M 20.62M 267M 20.74M 20.29M 884M P/E 2026 *
-1.29x
P/E 2027 * -1.71x
Enterprise Value 3.37M 2.9M 2.73M 2.49M 4.68M 320M 4.71M 32.3M 12.57M 163M 12.64M 12.37M 539M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
54.35%
Yield 2026 *
-
Yield 2027 * -
1 month-2.56%
3 months-20.83%
6 months-9.52%
Current year-5.00%
1 week 0.18
Extreme 0.18
0.2
1 month 0.16
Extreme 0.16
0.21
Current year 0.16
Extreme 0.16
0.27
1 year 0.16
Extreme 0.16
0.3
3 years 0.16
Extreme 0.16
2.52
5 years 0.16
Extreme 0.16
7.8
10 years 0.16
Extreme 0.16
33.1
Manager TitleAgeSince
Chief Executive Officer 64 01/10/2020
Director of Finance/CFO - 05/09/2023
Chief Tech/Sci/R&D Officer - 01/05/2021
Director TitleAgeSince
Director/Board Member - 14/10/2015
Director/Board Member 64 01/10/2020
Director/Board Member - 01/01/2024
Date Insider Type Main position Quantity % Market Cap. Importance
16/10/25
Tracarta Ltd.
BuyCompany 7,342,296 0.3448%
22/5/25 Others

Director

422,727,272 19.8499%
4/3/25 Buy

Chief Operating Officer

1,500,000 0.2945%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-20.83%-91.74% 5.53M
-0.25%-0.92%+49.47%+89.45% 68.13B
+1.21%+0.80%+46.29%+85.32% 63.6B
+1.31%-5.21%+37.52%+12.07% 25.57B
-0.25%-1.92%-10.72%+436.70% 26.6B
+0.33%-10.61%+1.95%-16.27% 25.52B
-6.09%-12.08%+226.11%+375.00% 18.23B
+1.18%-2.23%+30.87%-19.04% 19.69B
-1.49%-6.44%+0.78%+540.26% 15.16B
+4.12%+0.30%+52.03%+150.18% 13.54B
Average +0.01%-3.46%+41.35%+156.19% 27.61B
Weighted average by Cap. +0.15%-2.88%+45.22%+143.88%

Financials

2026 *2027 *
Net sales - -
Net income -3.38M -2.91M -2.74M -2.5M -4.7M -321M -4.72M -32.41M -12.62M -163M -12.69M -12.41M -541M -3.46M -2.98M -2.81M -2.56M -4.81M -328M -4.83M -33.17M -12.91M -167M -12.98M -12.7M -554M
Net Debt -2.16M -1.86M -1.75M -1.59M -3M -205M -3.01M -20.69M -8.05M -104M -8.1M -7.92M -345M -704K -607K -571K -520K -979K -66.81M -984K -6.75M -2.63M -33.98M -2.64M -2.59M -113M
Logo Theracryf Plc
TheraCryf plc is a clinical-stage drug development company focusing on brain disorders. The Company has a clinical and preclinical pipeline of indications, including addiction, anxiety, fatigue, narcolepsy, glioblastoma and neurodevelopmental disorders. Its lead program, orexin-1 antagonist, is being developed towards the clinic to target addictive behaviors like binge eating disorder (BED). It is also advancing a clinical-stage asset, SFX-01, in the fatal brain cancer glioblastoma (GBM). SFX-01 is a patented form of sulforaphane which has shown potential in the treatment of various cancers, neurodevelopmental disorders and other diseases. It has licensed the global rights for SFX-01 in neurodevelopmental disorders and schizophrenia to Stalicla. The Company also has a candidate molecule dopamine active transport (DAT) inhibitor at a late preclinical stage targeting fatigue and narcolepsy.
Employees
9
Date Price Change Volume
01/09/26 GBX 0.1900 0.00% 405,000
28/08/26 GBX 0.1900 0.00% 1,799,771
27/08/26 GBX 0.1900 0.00% 668,009
26/08/26 GBX 0.1900 0.00% 1,531,057
25/08/26 GBX 0.1900 0.00% 847,709
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.002570USD
Average target price
0.0431USD
Spread / Average Target
+1,578.40%

Annual profits - Rate of surprise